• Pharma
    Driving Progress in the Biosimilar Marketplace

    Oct 12, 2017

    In 2010, the Biologics Price Competition and Innovation Act (BPCIA) established an abbreviated approval pathway for “follow-on” biologics or biosimilar products. Since then, the market for biosimilars has been mired in uncertainty. The BPCIA contains language known as the “patent dance,” which has tied up the release of several biosimilar drugs. The patent dance instructs […]

  • Pharma
    Speeding Up Clinical Trials With Remote Monitoring Support

    Sep 28, 2017

    Manufacturers of medical devices have traditionally used time-intensive methods to gather data from clinical trial participants. They have either observed office visits or given participants paperwork to complete at home. Today, remote patient monitoring (RPM) can streamline the process, automating data collection and transmission. RPM involves mobile medical devices that send real-time data to clinical […]

  • Providers
    A New Era: Enabling Payor & Provider Collaboration

    Sep 14, 2017

    In today’s rapidly changing health care environment, one silver lining for providers is payers’ increasing interest in collaboration. Patients are switching insurance more frequently, often ending up with high-deductible plans. Meanwhile, providers face increasing amounts of paperwork, lowering the time they can spend on patient care. Providers and payers both benefit from increasing their partnership. […]

  • Pharma
    Gaining Access on Providers’ Terms

    Sep 7, 2017

    Pharmaceutical manufacturers want to increase their access to provider offices. But it’s not always clear how to do this, and manufacturers don’t always have the resources to support intensive provider contact. Meanwhile, providers’ overwhelming workloads can prevent them from seeking product information from manufacturers. To bridge this gap, manufacturers must listen actively to providers and […]

  • Pharma
    Reimbursement Hub Services: More Than a Point of Contact

    Aug 31, 2017

    Pharmaceutical manufacturers strive to get patients on therapy faster and minimize patient drop-off. Engaging the reimbursement hub services of a white-glove partner—such as WRB, an EnvoyHealth company—is a powerful way to improve efficiencies and ensure value. WRB’s white glove approach to its reimbursement service includes experienced reimbursement specialists supporting a patient’s needs throughout their journey.  […]

  • Pharma
    Prior Authorizations: Helping Patients Leap the Hurdles

    Aug 24, 2017

    A physician’s prescription does not ensure the patient will receive a medication—no matter how appropriate or effective. Payers increasingly require prior authorization (PA). Failure to procure one can mean claim denial, even if the drug was considered a covered expense. The prior authorization process presents barriers to patients—as well as to pharmaceutical manufacturers’ bottom lines. […]

  • Pharma
    Gamification: Leveling Up Patient Adherence

    Aug 17, 2017

    Gamification—using video game–like tasks to creatively engage patients and foster treatment adherence—is gaining traction in health care. Since the cost of nonadherence in the U.S. is estimated as high as $337.1 billion annually, it’s no wonder pharmaceutical and medical-device manufacturers are taking this novel approach. Examples of gamification include: Apps that give patients points for […]

  • Pharma
    Remote Patient Monitoring Market Continues to Grow

    Aug 10, 2017

    More than 7 million patients were enrolled in mobile health care programs in 2016, according to a report from Berg Insight. It predicts more than 50 million patients will be remotely monitored by 2021. Connected medical devices are integral to these patients’ care. Benefits of remote monitoring include: Reduction of hospital readmissions Prevention of unnecessary […]

  • Pharma
    A Closer Look at Drug Safety Reporting

    Aug 3, 2017

    Monitoring and reporting on drug safety is a critical function for pharmaceutical and medical device manufacturers, from clinical trials throughout the commercial life of the product. It is the most important tool they have to anticipate and resolve drug problems in the marketplace proactively. The two major prongs of drug safety reporting and feedback are […]

  • Pharma
    Orphan Drug Manufacturers: Consider This Market Access Strategy

    Jul 27, 2017

    Talking about orphan drugs is a must since orphan drugs are intended to treat rare diseases. Not to talk about orphan drugs would be unfair to approximately 25 million people in the U.S. with rare medical conditions. It is noteworthy, too, the FDA has an Office of Orphan Products Development whose “mission is to advance […]